Drugs / MAK683
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02900651 | Oct 2016 → Oct 2024 | diffuse large B-cell lymphoma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAK683 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02900651 ↗ |
| Action | Inhibit | “highly selective allosteric inhibitor of the embryonic ectoderm development subunit” PMID 39793445 ↗ Nov 2024 |
| Target | EED | “MAK683 (EED inhibitor)” PMID 39793445 ↗ Nov 2024 |